Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

被引：11

作者：

Gentile, Massimo ^{[1
]}

Shanafelt, Tait D. ^{[2
]}

Mauro, Francesca Romana ^{[3
]}

Reda, Gianluigi ^{[4
]}

Rossi, Davide ^{[5
]}

Laurenti, Luca ^{[6
]}

Del Principe, Maria Ilaria ^{[7
]}

Cutrona, Giovanna ^{[8
]}

Angeletti, Ilaria ^{[9
]}

Coscia, Marta ^{[10
]}

Herishanu, Yair ^{[11
,12
]}

Chiarenza, Annalisa ^{[13
]}

Molica, Stefano ^{[14
]}

Ciolli, Stefania ^{[15
]}

Goldschmidt, Neta ^{[16
]}

Angrilli, Francesco ^{[17
]}

Giordano, Annamaria ^{[18
]}

Rago, Angela ^{[19
]}

Bairey, Osnat ^{[20
,21
]}

Tripepi, Giovanni ^{[22
]}

Chaffee, Kari G. ^{[23
]}

Sameer, Parikh A. ^{[24
]}

Vigna, Ernesto ^{[1
]}

Zirlik, Katja ^{[25
]}

Shvidel, Lev ^{[26
,27
,28
]}

Innocenti, Idanna

Recchia, Anna Grazia ^{[29
]}

Di Raimondo, Francesco ^{[13
]}

Del Poeta, Giovanni ^{[7
]}

Cortelezzi, Agostino ^{[4
]}

Neri, Antonino ^{[4
]}

Ferrarini, Manlio ^{[30
]}

Gaidano, Gianluca ^{[31
]}

Kay, Neil E. ^{[2
]}

Polliack, Aaron ^{[16
]}

Foa, Robin ^{[3
]}

Morabito, Fortunato ^{[29
]}

机构：

[1] Osped Annunziata, UOC Ematol, Cosenza, Italy

[2] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA

[3] Univ Sapienza, Ematol, Rome, Italy

[4] Univ Milan, Osped Maggiore Policlin, Fdn Ca Granda IRCCS, Unita Ematol, Milan, Italy

[5] Oncol Inst Southern Switzerland, Inst Oncol Res, Bellinzona, Switzerland

[6] Univ Cattolica A Gemelli Rome, Dipartimento Ematol, Rome, Italy

[7] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenzione, Ematol, Rome, Italy

[8] IRCCS S Martino IST, UOC Patol Mol, Genoa, Italy

[9] Azienda Osped Santa Maria Tern, Reparto Oncoematol, Terni, Italy

[10] Univ Torino, AO Citta Salute & Sci Torino, Div Ematol, Turin, Italy

[11] Tel Aviv Univ, Tel Aviv Sourasky Med, Dept Hematol, Tel Aviv, Israel

[12] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[13] Univ Catania, Osped Ferrarotto, Div Ematol, Catania, Italy

[14] Azienda Osped Pugliese Ciaccio, Dipartimento Oncoematol, Catanzaro, Italy

[15] Univ Firenze, Ematol, Florence, Italy

[16] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Hematol, Jerusalem, Israel

[17] Osped Spirito Santo, Dipartmento Ematol, Pescara, Italy

[18] Ematol Azienda Osped Univ, Policlin Consorziale Bari, Bari, Italy

[19] Osped Santa Maria Goretti, UOC Ematol, Latina, Italy

[20] Rabin Med Ctr, Dept Hematol, Petah Tiqwa, Israel

[21] Tel Aviv Univ, Sackler Fac Med, Petah Tiqwa, Israel

[22] CNR, Ist Biomed & Immunol Mol, Reggio Di Calabria, Italy

[23] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA

[24] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

[25] Univ Med Ctr Freiburg, Dept Haematol & Oncol, Freiburg, Germany

[26] Kaplan Med Ctr, Dept Hematol, Rehovot, Israel

[27] Hadassah Med Ctr, Jerusalem, Israel

[28] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[29] Azienda Sanit Provinciale Cosenza, Unita Ric Biotecnol, Aprigliano, CS, Italy

[30] Direzione Sci IRCCS, San Martino IST, Genoa, Italy

[31] UPO, Dept Translat Med, Div Haematol, Novara, Italy

来源：

EUROPEAN JOURNAL OF HAEMATOLOGY | 2018年 / 101卷 / 05期

关键词：

chemo-immunotherapy; chronic lymphocytic leukemia; CLL-IPI; PFS; prognosis; progression-free survival; CHRONIC LYMPHOCYTIC-LEUKEMIA; PREVIOUSLY UNTREATED PATIENTS; PROGNOSTIC INDEX; RITUXIMAB; CYCLOPHOSPHAMIDE; BENDAMUSTINE; FLUDARABINE; TRIAL; COMBINATION; MULTICENTER;

D O I：

10.1111/ejh.13149

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：703 / 706

页数：4

共 50 条

[1] Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) in previously untreated CLL patients receiving chemo-immunotherapy as first-line approach: analysis of 529 cases
Gentile, Massimo
Mauro, Francesca Romana
Reda, Gianluigi
Rossi, Davide
Laurenti, Luca
Del Principe, Maria Ilaria
Vergata, Tor
Cutrona, Giovanna
Angeletti, Ilaria
Coscia, Marta
Herishanu, Yair
Chiarenza, Annalisa
Molica, Stefano
Ciolli, Stefania
Goldschmidt, Neta
Morabito, Fortunato
Gaidano, Gianluca
Polliack, Aaron
Cortelezzi, Agostino
Innocenti, Idanna
Bairey, Osnat
Shvidel, Lev
Angrilli, Francesco
Giordano, Annamaria
Uccello, Giuseppina
Petrungaro, Annamaria
Vigna, Ernesto
Rago, Angela
Tripepi, Giovanni
ZirliK, Katja
Recchia, Anna Grazia
Di Raimondo, Francesco
Del Poeta, Giovanni
Vergata, Tor
Ferrarini, Manlio
Foa, Robin
Neri, Antonino
[J]. LEUKEMIA & LYMPHOMA, 2017, 58 : 131 - 133
[2] Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
van Gelder, M.
Tournilhac, O.
te Raa, D.
Visser, H. P. J.
[J]. ANNALS OF ONCOLOGY, 2021, 32 (11) : 1442 - 1443
[3] ASSESSING TIME TO FIRST TREATMENT IN EARLY CLL: A COMPARATIVE PERFORMANCE ANALYSIS OF FIVE PROGNOSTIC MODELS WITH INCLUSION OF CLL-IPI
Molica, S.
Giannarelli, D.
Gentile, M.
Mirabelli, R.
Levato, L.
Morabito, F.
[J]. HAEMATOLOGICA, 2016, 101 : 434 - 434
[4] First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
Urso, Antonio
Cavazzini, Francesco
Ballardini, Maria Pia
Gambara, Silvia
Consolo, Sara
Rigolin, Gian Matteo
Cuneo, Antonio
[J]. CANCERS, 2023, 15 (15)
[5] Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis
Molica, Stefano
Giannarelli, Diana
Levato, Luciano
Mirabelli, Rosanna
Gentile, Massimo
Morabito, Fortunato
[J]. BLOOD, 2015, 126 (23)
[6] Chemo-immunotherapy - the role of monoclonal antibodies for the treatment of chronic lymphocytic leukemia (CLL)
Hallek, M
Wendtner, CM
Fingerle-Rowson, G
Fischer, K
Goede, V
Schweighofer, C
Fink, AM
Elter, T
Kofler, D
Busch, R
Emmerich, B
Eichhorst, B
[J]. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2005, 55 (11): : 704 - 705
[7] Ibrutinib and Venetoclax for First-Line Treatment of CLL
Jain, Nitin
Keating, Michael
Thompson, Philip
Ferrajoli, Alessandra
Burger, Jan
Borthakur, Gautam
Takahashi, Koichi
Estrov, Zeev
Fowler, Nathan
Kadia, Tapan
Konopleva, Marina
Alvarado, Yesid
Yilmaz, Musa
DiNardo, Courtney
Bose, Prithviraj
Ohanian, Maro
Pemmaraju, Naveen
Jabbour, Elias
Sasaki, Koji
Kanagal-Shamanna, Rashmi
Patel, Keyur
Jorgensen, Jeffrey
Garg, Naveen
Wang, Xuemei
Sondermann, Katrina
Cruz, Nichole
Wei, Chongjuan
Ayala, Ana
Plunkett, William
Kantarjian, Hagop
Gandhi, Varsha
Wierda, William
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (22): : 2095 - 2103
[8] Factors influencing First-Line Treatment in CLL
Dilhuydy, Marie-Sarah
[J]. HEMATOLOGIE, 2024, 30 : 13 - 18
[9] Ibrutinib and Venetoclax for First-Line Treatment of CLL
Kater, Arnon P.
Levin, Mark-David
Niemann, Carsten U.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (08): : 788 - 789
[10] Chemo-immunotherapy as first-line treatment for small-cell lung cancer
Farid, Saira
Liu, Stephen V.
[J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12

← 1 2 3 4 5 →